We also identified new mutations in the CDK and PI3K/AKT/mTOR pathways in clear cell RCC brain metastasis tumors, while a melanoma brain metastasis also showed a single new CDKN1B gene mutation, suggesting the potential for CDK inhibitor therapy in these patients. This evidence concerns the gene MTOR and metastasis.